Preview: Indy 500 Puts Face on Afrezza

When the Indianapolis 500 takes place on May 26, an unlikely competitor will take part in the race: MannKind Corp. In an attempt to jumpstart sales for its inhalable insulin Afrezza, the Westlake Village-based biomedical company has signed a marketing agreement with racecar driver Conor Daly, who has Type 1 diabetes. The driver will make his debut with the Andretti Autosport team at the Indy 500. For the company, the race already appears a win-win. The biomedical company plans to use its associate sponsorship of Daly to raise awareness regarding diabetes treatment options. The campaign also links Daly’s human-interest story about living with diabetes to the Afrezza brand. Read the full story in the April 1 issue of the San Fernando Valley Business Journal.